Healthy vision empowers individuals and their families to pursue their passions and focus on life’s brilliance.
We believe that the gift of superior vision can be life-changing to people affected by blinding eye diseases. Superior vision empowers them to enjoy fuller and healthier lives.
We are dedicated to making a real difference. That’s why we are fearless in our pursuit of pushing the boundaries of what’s possible to improve sight.
Our Vision: Pioneering Innovation to Improve Sight
We are a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, like wet age‐related macular degeneration (wet AMD) and diabetic macular edema (DME), which remain leading causes of vision loss worldwide.
Our lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D ‘trap’ inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients.
Sozinibercept has the potential to become the first therapy in 20 years to enable patients with wet AMD live fuller and healthier lives.
Our Team: Dedicated to Deliver Superior Vision for Fuller and Healthier Lives.
Our Team: Dedicated to Deliver Superior Vision for Fuller and Healthier Lives.
Our team’s deep expertise in retina, global business experience, and determination to make a real difference in the lives of people affected by blinding eye diseases, drives our work and decisions, every day.
We are supported by expert board members as well as global thought leaders in retina who share our dedication to deliver superior vision for fuller and healthier lives.
Our culture: grounded in compassion, courage and commitment
We do what’s right to improve the lives of patients and their families.
We act with integrity and kindness, always.
We respect diverse opinions because they make us stronger.
We break through barriers to achieve the unprecedented.
We are unstoppable when facing setbacks or adversity.
We embrace the innovation to reach the highest standards.
We are disciplined to deliver superior results.
We nurture deep relationships and build trust.
Only through collaboration can we make a meaningful impact.
“I was raised by my grandmother who never saw me. She was blind due to diabetic retinopathy. I saw her struggle with everyday tasks. She had burns all over her hands from touching the stove because she could not see. Her only wish was to see her grandchildren. As a physician-scientist this childhood experience still drives me to save sight. I am excited to join Opthea because I love the team’s passion to achieve the unprecedented – deliver superior vision to wet AMD patients”
“I’m honored to be part of the incredibly talented team at Opthea whose bold science has the potential to do what hasn’t been done before: enhance vision beyond current standard of care for wet AMD patients and potentially other significant retinal diseases. I’m excited to help patients see better to live better.”
“Helping people preserve their eyesight, independence, and connection to the world is what drives me. I’m excited to be part of the Opthea team who is pioneering new solutions for retinal diseases, offering real hope to patients who need better options to restore and maintain their vision.”
“I am thrilled to be part of Opthea who is dedicated to developing next-generation retinal therapies, like sozinibercept. Executing clinical trials with excellence and quality is my passion, and I am hopeful that our efforts will lead to significant visual improvements for wet AMD patients.”
“I had the privilege of being part of the first anti-VEGF-A launch in wet AMD and seeing how patients’ vision and quality of life improved. Now fast forward almost 20 years, I am excited to be part of Opthea whose ambitious goal is to bring even better vision to wet AMD patients. We have a tremendous opportunity to give those patients the confidence to expect more from their treatment.”
